Articles, guides, and regulatory updates from our community.
A 2026 rat study suggests BPC 157 may reduce oxidative stress and muscle damage from ischemia-reperfusion injury. Learn what the research found.
By Peptide Association Research Team
New research on GHK-Cu peptide in aged mice suggests delivery route may shape cognitive and molecular outcomes. Learn what the findings mean for aging research.
By Peptide Association Research Team
New rat study suggests BPC 157 may reduce oxidative stress and tissue damage from ischemia-reperfusion injury. Read the findings and what they mean for research.
By Peptide Association Research Team
New research suggests SS-31 (Elamipretide) may modulate alpha-synuclein aggregation and restore mitochondrial function in Parkinson's-related models.
By Peptide Association Research Team
New research suggests the mitochondria-targeted peptide SS-31 may help protect cardiac function during doxorubicin chemotherapy. Learn what the study found.
By Peptide Association Research Team
New research suggests the peptide SS-31 (Elamipretide) may modulate α-synuclein aggregation and restore mitochondrial function linked to Parkinson's disease.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's development barriers, formulation challenges, and why human clinical data remains critically limited.
By Peptide Association Research Team
New rat study suggests BPC 157 may reduce oxidative stress and tissue damage from ischemia-reperfusion injury. Learn what the research shows and its limitations.
By Peptide Association Research Team
New research explores repurposed drugs targeting Alzheimer's disease pathways. Learn what the latest evidence suggests about emerging therapeutic strategies.
By Peptide Association Research Team
New research suggests the mitochondria-targeted peptide SS-31 may help protect cardiac function during doxorubicin chemotherapy by reducing oxidative stress.
By Peptide Association Research Team
New rat study suggests BPC 157 may reduce oxidative stress and tissue damage from ischemia-reperfusion injury. Learn what the research shows and its limitations.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's biopharmaceutical challenges, pharmacokinetic gaps, and the barriers standing between preclinical promise and human trials.
By Peptide Association Research Team
A 2026 rat study found BPC 157 may reduce oxidative stress and apoptosis in lower limb ischemia-reperfusion injury. Learn what the research suggests.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines why BPC-157 lacks approved formulations, validated dosing, and completed Phase II trials despite 30+ years of preclinical data.
By Peptide Association Research Team
A 2026 rat study suggests BPC 157 may protect against ischemia-reperfusion injury by reducing oxidative stress, inflammation, and cell death. Learn what the research shows.
By Peptide Association Research Team
New research explores how mitochondria-targeted peptide nanoparticles may protect the liver from ischemia-reperfusion injury. Learn what the science shows.
By Peptide Association Research Team
A 2026 review in JBJS Reviews examines the evidence, safety, and antidoping implications of injectable peptides used in sports medicine and orthopaedics.
By Peptide Association Research Team
A 2026 ACS Nano study suggests mitochondria-targeted nanoparticles may reduce liver ischemia-reperfusion injury by limiting ROS and inflammation in mice.
By Peptide Association Research Team
A 2026 structured review examines injectable peptides for musculoskeletal recovery. Learn what the evidence, safety data, and antidoping rules mean for athletes.
By Peptide Association Research Team
New research explores how mitochondria-targeted polydopamine nanoparticles modified with SS-31 peptide may protect the liver from ischemia-reperfusion injury.
By Peptide Association Research Team
New research across 85 trials finds incretin-based therapies modestly reduce blood pressure and lower mortality in adults with obesity. Read the evidence.
By Peptide Association Research Team
New research explores retatrutide's role in CKM syndrome, showing significant weight loss, glycemic control, and cardiorenal benefits in Phase 2 trials.
By Peptide Association Research Team
New research reframes how the MASCC Risk Index predicts febrile neutropenia complications using likelihood ratios and Bayesian probability for better bedside decisions.
By Peptide Association Research Team
New research on retatrutide shows promising weight loss and metabolic results. Learn what the 2026 clinical review found about this triple hormone receptor agonist.
By Peptide Association Research Team